The Tennor Therapeutics Zhongshan company's industrial building, located in the second phase of Zhongshan Life Science Park, was topped out on January 2.

Tennor Therapeuticsis a clinical needs-oriented company that focuses on the development of differentiated new drug products against bacterial infections and metabolic related diseases.

In October 2024, the Tennor Zhongshan project settled in Zhongshan Life Science Park, with a leased area of more than 10,000 square meters and a planned investment of 300 million yuan. It includes an industrial production base and a settlement center. The company's innovative drug pipelines will also be transferred to Zhongshan.

Currently, three of Tennor Therapeutics' products are under the late-stage clinical trials, one of which was rated by The Lancet as the first new drug developed against H. pylori infection in the world in the past 30 years. It is expected to overcome the problem of antibiotic resistance.

The second phase of Zhongshan Life Science Park, equipped with professional facilities related to biomedicine, is planned to go into operation by the end of 2025.